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Introduction
Paclitaxel (PX) has been reported to demonstrate a significant anticancer activity against ovarian carcinoma, head and neck cancers, breast cancer, lung cancer and AIDS related Kaposi's sarcoma (Rowinsky and Donehower, 1995) . Despite its promising efficacy, the clinical use of paclitaxel is limited by its poor water-solubility as well as low cellular permeability (Wani et al., 1971 , Panchagnula, 1998 , Singla et al., 2002 , Yoshizawa et al., 2014 . For clinical administration of paclitaxel, the drug is dissolved in Cremophor ® EL (Poly-oxyethylated castor oil) and ethanol (50:50 v/v) followed by dilution by 5-20 times before parenteral injection; the marketed formulation with this vehicle system is Taxol ® .
Unfortunately, Cremophor EL causes serious toxic effects such as nephrotoxicity, hypersensitivity reactions, neurotoxicity, laboured breathing, hypotension and lethargy (Singla et al., 2002) . Therefore, replacing Cremophor ® EL by a biocompatible formulation that can also increase aqueous solubility and improve therapeutic efficacy of the drug is highly needed (Kadam et al., 2014) . Abraxane ® is an FDA approved nanomedicine formulation of paclitaxel attached with albumin nanoparticles (Garber, 2004) . Clinical investigations have demonstrated that Abraxane ® can offer 14% higher response rate and 33% greater tumour penetration than Taxol ® (Garber, 2004) . However, obtaining large quantities of human albumin is expensive, thus designing alternative nanomedicines that are safe and economically affordable is highly desirable.
Liposomal-based formulations have been suggested as 'non-toxic' nanomedicines, owing to the great similarity of the liposomal phospholipids with biological membranes; this makes liposomes highly biocompatible and biodegradable (Crosasso et al., 2000, Koudelka and Turánek, 2012) .
Incorporation of PX in liposomes can reduce the drug toxicity to normal tissues and eliminate the hypersensitivity reactions caused by Cremophor EL vehicle. Liposomes also reduce the dose-limiting toxicity of PX by significant elevation of the maximum tolerated dose (MTD) of the drug (Sharma et al., 1993 , Cabanes et al., 1998 , Fetterly and Straubinger, 2003 .
Intracranial administration of liposomal paclitaxel in rat brain tumor model has shown to increase the life span in the animals to up to 40% compared to cremophor EL and ethanol mixture formulations (Zhou et al., 2010) . Lipusu® (Luye Pharma Group) is a paclitaxel liposomal formulation that has recently been commercialized and recommended for the treatment of breast, ovarian and non-small cell lung cancer (Koudelka and Turánek, 2012, Wang et al., 2013) .
A major limitation of liposomes is their poor stability, owing to oxidation and hydrolysis of the phospholipids. Proliposome technologies such as particulate-based proliposomes (Payne et al., 1986a , Payne et al., 1986b and ethanol (solvent)-based proliposomes (Perrett et al., 1991) have been advocated to overcome the instability manifestations of liposomes and provide convenient and economic options when compared to spray-drying or freeze-drying of liposomes. Ethanol-based proliposomes are ethanolic lipid solutions which, depending on the hydration procedure, generate oligolamellar liposomes (Perrett et al., 1991) or multilamellar vesicles (Turánek et al., 1997) . Proliposomes can also offer a feasible approach for manufacturing liposome precursors on a large scale, (Gala et al., 2015) thus overcoming the instability problems (liability of phospholipid to hydrolysis, oxidation and subsequent leakage of entrapped drug), high costs and unsuitability of conventional thin-film made liposomes for large scale production (Kensil and Dennis, 1981, Grit et al., 1989) .
Liposomes prepared by ethanol-based proliposome method have been shown to provide high entrapment efficiency for hydrophilic drugs. The entrapment efficiency ranged from 60 to 80% depending on the composition of phospholipid (Perrett et al., 1991) and 30 to 85% depending on the hydration protocol of the proliposomes (Turánek et al., 1997 , Elhissi et al., 2006 .
Noteworthy, that hydration temperature employed was important at influencing the entrapment efficiency as high temperature (60°C) provided an effective entrapment (approx. 80%) rather than at low temperature (20°C)
where the entrapment was around 50% (Turánek et al., 1997) . Hydrophobic drugs may also have high entrapment efficiencies in these liposomes.
Entrapment efficiencies of 93 to 98% have been reported for levonorgestrel depending on type of alcohol employed in the formulation (Deo et al., 1997) .
In this study, we have introduced paclitaxel-loaded liposomes prepared via the ethanol-based proliposome technology using various lipid compositions.
Physicochemical properties of formulations such as size, size distribution, zeta potential, pH, vesicle morphology and drug entrapment efficiency were studied. Moreover, the cytotoxicity of the formulations on grade IV glioma (U87-MG) and normal glial (SVG-P12) cell lines was investigated.
Methods

Materials
Soya phosphatidylcholine (SPC; Lipoid S-100), hydrogenated phosphatidylcholine (HSPC; Phospholipon 90H) and dipalmitoyl phosphatidylcholine (DPPC) were obtained and Human glial cell line (SVG-P12) were obtained from European collection of cell cultures, UK. Paclitaxel (PX) was purchased from ChemieTek, USA.
Preparation of Liposomes
The lipid phase (phospholipid: Chol, 1:1 mole ratio) (50 mg) was dissolved in absolute ethanol (75 μl) at 70°C (water bath) for 1 min within a 15 ml glass vial. Paclitaxel was then added in the ethanolic solution to produce a range of concentrations in the subsequent aqueous dispersion (0.1, 0.3, 0.5 and 1 mg per ml of the final liposomal dispersion).
Aqueous (water) phase (10 ml), significantly above the Tm of the lipid was added immediately to avoid lipid phase solidification. Liposomes were generated upon vigorous hand shaking and vortex mixing (Fisons Whirlimixer, UK) for 4 min. Liposomal formulations were then kept for annealing above the Tm of the lipids for 2 h followed by size, zeta potential measurements and electron microscopy studies.
Size Reduction of Liposomes
Liposome dispersions (10 ml) were probe-sonicated (Sonics Vibra-cell-CV33, USA) at the highest frequency for a maximum of 10 min with intermittent cooling to avoid excessive heating of the liposomes. The resultant dispersion (except for those of the entrapment determination) was centrifuged (Jouan Robotics A-14, France) at 10,000 rpm (9,200 g) for 2 min to remove the titanium particles leached from the probe of the sonicator.
Laser Diffraction Size Analysis for Liposomes Before Size Reduction
Laser diffraction technique was used for size analysis of liposomes. The measurements were performed using the Malvern Mastersizer 2000 (Malvern instruments Ltd., UK).
This was carried out by addition of 70 ml of deionised water to the cone dispersion unit (Hydro2000 SM, UK) of the instrument. Size and size distribution were presented as the volume median diameter (VMD) (50% undersize) and Span respectively. Span = (90% undersize -10% undersize) / VMD.
Photon Correlation Spectroscopy (PCS) Analysis After Size Reduction
Photon correlation spectroscopy (PCS) technique relies on the Brownian motion of the particles using the Zetasizer instrument (Zetasizer nano, Malvern Instruments Ltd., UK).
The size and polydispersity of the sonicated liposomes (in the supernatant; i.e. following removal of titanium particles) were analyzed by recording the hydrodynamic diameter (Zaverage) and polydispersity index (PI) respectively using the Zetasizer instrument (Zetasizer nano, Malvern Instruments Ltd., UK).
Determination of Drug Entrapment Efficiency
Entrapment efficiency of PX was determined by adapting the separation methods previously used by Kumar et al (2001) and Gala et al (Gala et al., 2015) . Liposome suspension was passed through syringe filters (0.45 µm) at least three times. The filter was then washed with HPLC water until the solution ran clear. Then, the filter was placed in absolute ethanol and paclitaxel was extracted. The extracted fraction was collected to determine the proportion of un-entrapped drug using Dionex Ultimate 3000 UHPLC with
BetaBasic column 18 particle size 5µm, pore size 150A, 150mm L x 4.6mm I.D. Mobile phase; acetonitrile: water:methanol (55:45:5) at wavelength 227nm, retention time was 5.6 min. This amount was subtracted from the total amount of PX in the liposomes to calculate the amount of entrapped drug. The solubility of paclitaxel in water is less than 0.1 μg/mL (Konno et al., 2003) , therefore, the amount of the drug dissolved in water during hydration was ignored. The entrapment efficiency (EE) of paclitaxel (PX) in liposomes was calculated using the following equation:
(%) = Amount of PX entrapped Total amount of PX in liposome formulation x 100
Cytotoxicity Study (MTT Assay)
The U87-MG cells (grade IV glioma, passage 13) and SVG-P12 (glial cells, passage 7)
were seeded at 1 x10 5 cells/well in 96-well plates and maintained at 37 o C in an atmosphere of 5% CO2 and 95% relative humidity in Eagle's minimum essential medium (EMEM) supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine and 0.1 mM non-essential amino acids. Prior to assay, loaded liposomal formulations of 1 mg/ml were filtered through a 0.4 µm sterile syringe filters to remove unloaded paclitaxel.
Considering the loading efficiency ( Figure 5 ), filtered formulations were used as stocks diluted by media to yield 1, 2.5, 5, 25, 50, 250, 500, 1500 nM of loaded paclitaxel.
After 24 containing cells as 100% (Yang et al., 2007) .
Statistical Analysis
Statistical significance was measured using the one-way analysis of variance (ANOVA) and student's t-tests as appropriate. All values were expressed as the mean ± standard deviation. Values of P < 0.05 were regarded as significantly different.
Results and Discussion
Size Analysis and Microscopic Morphology of Liposomes Before Sonication
The influence of paclitaxel concentration and phospholipid composition on size distribution of the liposomes generated from ethanol-based proliposomes was investigated. Figure 1a shows the effect of paclitaxel concentration on the VMD of the formulated liposomes. The VMD of SPC-liposomes containing PX at 0.5 mg/ml (3.78 ± 0.08 µm) and 1 mg/ml (3.83 ± 0.09 µm) concentrations were larger than VMD of paclitaxel-free SPC-liposomes (3.12 ± 0.07 µm) (P<0.05). However, the VMD of PX-SPC-liposomes containing low PX concentration showed no significant difference when compared to that of PX-free SPC-liposomes (P>0.05). This suggests that the VMD of SPC-liposomes was increased by increasing drug concentration (0.5 and 1 mg/ml) but not at lower PX concentrations (0.1 and 0.3 mg/ml).
The VMDs of HSPC-liposomes containing PX were higher than that of drug- The VMD measurements of HSPC-based liposomes were higher than those of the corresponding DPPC-based liposomes (P<0.05). Amongst the phospholipids used, PX concentration was most influential to the size of vesicles made from HSPC:Chol (1:1). This is possibly attributed to the higher hydrophobicity of the longer acyl chains in HSPC phospholipid and repulsive interactions between water molecules at the interface, causing the vesicles to aggregate (Zhao and Feng, 2004 , Zhao and Feng, 2005 , Zhao et al., 2007 .
Size distribution of liposomes was represented by the measurement of Span, a term introduced by Malvern Instruments Ltd to express the polydispersity of particles. In general, no effect was seen on the Span of liposome TEM studies have shown that liposomes prior to probe-sonication were multilamellar vesicles (MLVs) and that was independent of drug concentration or lipid composition (images not shown). This agrees with our previous publication of liposomes prepared using the ethanol-based proliposome technology (Elhissi et al., 2006) . Studies by other investigators have shown that liposomes generated from ethanol-based proliposomes were oligolamellar (Perrett et al., 1991) or multilamellar (Turánek et al., 1997) .
Size Analysis of Liposomes After Sonication
Size of liposomes was reduced aiming to convert multilamellar vesicles (MLVs) into small unilamellar vesicles (SUVs) having a size range around 100 nm. After probe sonication, the size of liposomes was decreased by approximately 95% or more (compared to size of initial MLVs), regardless of formulation ( Figure 1a and Figure 2a ).
This indicates that drug inclusion and lipid composition did not retard size reduction and hence MLVs were successfully fragmented into nano-liposomes (100-200 nm) ( Figure   2a ). Moreover, liposomes made from HSPC:Chol (1:1) had larger size than liposomes made from DPPC:Chol (1:1) or SPC:Chol (1:1). These results correlate with TEM images ( Figure 1S ) for the 1 mg/ml PX concentration for SPC, HSPC and DPPC liposomes respectively. The TEM-images were taken after probe-sonication and clearly showed that vesicles were SUVs. The size of SPC, HSPC and DPPC liposomes according to TEM were approx. 125 nm, 175 nm and 155 nm respectively ( Figure 1S ). This indicates that size of sonicated vesicles was affected by lipid phase composition. Noteworthy, the effect of PX concentration on liposome size after sonication was minimal (Figure 2a ).
The polydispersity index (PI) for all liposomes was found to be below 0.3 (Figure 2b ), indicating that sonication has generated liposomes with relatively narrow size distribution, regardless of lipid type and drug concentration.
However, an inconsistent effect of PX on polydispersity of the liposome vesicles was shown in Figure 2b as it is difficult to correlate PX concentration with the PI value, regardless of phospholipid type. Overall, the low PI for all formulations indicates that the sonication time selected was appropriate and no further size reduction was required.
Zeta Potential Analysis Before Sonication
The zeta potential of all liposome formulations before sonication were in the negative range ( Figure 3a) . The average zeta potential of PX-free SPC-liposomes was -1.82 mV ± 0.09 which increased to -3.57 mV ± 0.28 upon inclusion of 0.1 mg/ml paclitaxel (P<0.05).
However, inclusion of higher concentrations of paclitaxel tended to reduce the charge intensity ( Figure 3a) . Overall, only a slight or no difference in zeta potential values were observed when drug-free liposomes were compared to liposomes having the highest PX concentration (i.e. 1mg/ml). It is possible that changes in zeta potential are related to changes in the VMD of liposomes (Ofir et al., 2007 , Elhissi et al., 2013 . Further research is required to understand why the negative zeta potential tended to increase at low drug concentration and revert to the original value upon inclusion of higher drug concentrations.
Zeta Potential Analysis After Sonication
The zeta potential of probe-sonicated liposomes was significantly lower than that of liposomes before size reduction, regardless of formulation. Furthermore, for SPC and HSPC-made liposomes, significant effects (P<0.05) of drug concentration on the zeta potential were observed (Figure 3b) . For HSPC or SPC liposomes at low drug concentrations (0.1 or 0.3 mg/ml), the zeta potential was approximate to neutrality (i.e.
0.00 mV). In contrast, DPPC-made vesicles showed more negative values. This may indicate that DPPC-made nano-liposomes are the most stable vesicles among the liposome formulations after sonication as the electrostatic repulsion between negatively charged DPPC vesicles may reduce aggregation (Howard and Levin, 2010) .
The increased negativity of zeta potential for the PX-SPC and PX-HSPC liposomes as a result of increasing the drug concentration was only a slight trend. However, statistically significant differences between the formulations depending on the composition of phospholipid were observed (Figure 3b ).
Compared with liposomes prior to sonication (Figure 3a) , the zeta potential of PX-free SPC-liposomes after sonication was almost neutral whereas the zeta potential of PX-SPC-liposomes containing the maximum drug concentration decreased in intensity by approximately 54% when compared to that of pre-sonicated PX-SPC liposomes (Figure 3a and b) . This suggests that vesicle size has an effect on zeta potential values, agreeing with previous investigations (Howard and Levin, 2010) .
pH Measurement of Liposome Formulations
The effect of drug concentration and lipid composition on the pH of liposomes was investigated. The pH of all SPC and HSPC liposomes was slightly acidic, while the pH of DPPC-liposomes was neutral to slightly basic (Figure 4) . It is worth mentioning that the pH of formulations increased by increasing PX concentration. For SPC-liposomes, the pH of PX-free liposomes was 6.06 ± 0.01 whereas the pH of liposomes having the maximum PX concentration was 6.72 ± 0.02 (P<0.05). Similarly, the pH of PX-free HSPC liposomes was 6.08 ± 0.03 while the pH of liposomes with maximum drug concentration was 6.84 ± 0.2 (P<0.05). The pH of formulations was the highest for DPPC liposomes followed by HSPC and then SPC formulations. The pH of SPC and HSPCliposomes increased gradually by increasing the drug concentration (P<0.05). However, the pH of DPPC-liposomes remained the same until 0.5 mg/ml PX concentration with no significant difference. It can be concluded that differences in the pH of liposome formulations made using different lipids at similar PX concentrations were minimal. The pH of DPPC liposomes seems to be the closest to that of the physiological fluids (pH 7.4).
Thus, amongst the various phospholipids used in this study, DPPC seems to be the most appropriate excipient for manufacturing liposome delivery systems for the anticancer drug paclitaxel.
Entrapment Efficiency of PX in Liposomes
According to Figure 5a , the entrapment efficiency of PX decreased with the increase in drug concentration (P<0.05) and that was independent of phospholipid composition. For example, the entrapment efficiency of the drug in DPPC-liposomes was 92.3% ± 2.7 for 0.1 mg/ml and decreased by 57% using 1 mg/ml PX concentration (35.3% ± 1.8) (P<0.05). However, the entrapment efficiency in DPPC liposomes was generally higher than that in SPC and HSPC vesicles (Figure 5a Similarly, DPPC-liposomes displayed an increase in the entrapped PX by increasing its initial loaded concentrations; with the highest PX concentration (10 mg /10 ml), the amount of drug entrapped was around 3.5 mg, which was higher than the maximum amount of drug entrapped in SPC or HSPC-made liposomes of the same loaded drug concentrations (figure 5b). According to Previous studies suggested that the molecular interaction between PX and lipid was facilitated by including cholesterol in the DPPC/PX mixed bilayers;
this made a more stable tertiary system of paclitaxel, cholesterol and DPPC (Zhao et al., 2007) . Cholesterol containing liposomes are generally more rigid and stable than liposomes made from phospholipid alone. DPPC-liposomes possess two thermal transitions: a sharp acyl chain melting transition temperature of 42.3 °C and a pre-transition temperature of 35.4°C (Zhao et al., 2007) . Incorporation of PX can eliminate the pre-transition temperature without changing the main phase transition temperature, leading to a flexible bilayer (Zhao et al., 2007) . PX is localized in C1-C8 carbon atoms of the acyl chain i.e. in the outer hydrophobic bilayer zone of DPPC liposomes and binds to the carbon atoms of DPPC by its C13 side chain, which is hydrophobic due to the presence of two aromatic rings (Balasubramanian and Straubinger, 1994, Zhao et al., 2007) .
It has also been found that the stability of PX in saturated phospholipids is dependent on the chain length, with DPPC (16:0), (number of carbons in the fatty acid chains and the degree of unsaturation), liposomes being more capable of entrapping higher proportions of paclitaxel than HSPC (18:0) liposomes (Zhao and Feng, 2004) . The interaction between phospholipid and PX has been reported to be nonspecific and dependent on the hydrophobic binding or van der Waals forces. The stronger van der Waals interactions in the longer chain can hinder the movement of paclitaxel in the bilayers. This forms unstable systems when compared to phospholipids with shorter acyl chain (Zhao and Feng, 2004) . This may explain the higher entrapment efficiency using DPPC (shorter chain) liposomes compared to HSPC vesicles.
DPPC possesses a first-order phase transition, a transition between liquidexpanded and liquid-condensed states, whereas HSPC possess only liquidcondensed phase. This may be due to the higher hydrophobicity of longer acyl chain phospholipids (of HSPC) and the lower possibility to exist in the tilted liquid-expanded state due to repulsive interactions between water molecules at the interface Feng, 2004, Zhao and Feng, 2005) . This might also explain the lower entrapment efficiency of HSPC compared to that of DPPC.
Some studies have suggested that naturally occurring or unsaturated phospholipid such as SPC can entrap hydrophobic drugs more efficiently compared to HSPC due to their low gel to liquid-crystalline phase transition temperature (Tm= -20°C) (Darwis and Kellaway, 2001, Kan et al., 2011) .
The liposomes prepared from this type of phospholipid along with cholesterol, are flexible enough to entrap greater proportions of the hydrophobic molecules (Kirby et al., 1980 , Senior and Gregoriadis, 1982 , Zhang et al., 2005 . Thus, liposomes prepared from HSPC liposomes are highly rigid and can limit the penetration of hydrophobic drugs. However, DPPC-liposomes have shown high molecular interactions with PX due to their first-order phase transition behaviour Feng, 2004, Zhao and Feng, 2005) . It has also been shown that PX interaction with lipid bilayers causes an increase in the surface charge intensity of the liposomes. This property is dependent on high molecular interactions between PX and phospholipids. Negative charge may increase the physical stability of liposomes by minimizing their fusion and aggregation (Kan et al., 2011) .
Thus, the difference in zeta potential with different PX concentrations may correlate with the different entrapment efficiency using liposome formulations with different lipid compositions. Figure 3b and Figure 5b clearly represented that higher drug concentrations have conferred more negative surface charge on the DPPC liposomes. The ability of higher drug concentrations to exert that effect on SPC and HSPC vesicles was comparatively less, which correlates well with the entrapment efficiency findings.
Cytotoxicity Studies
The cytotoxicity of liposomes loaded with a range of paclitaxel concentrations against U87-MG grade IV glioma and SVG-P12 glial cell lines was determined using the MTT assay. Figure Table 2 ).
The less toxic trend of PX-liposomes formulations may be attributed to the sustained release of paclitaxel from the loaded liposomes contacting the cells and medium (Crosasso et al., 2000 , Yang et al., 2007 . Furthermore, it has been indicated that incorporating cholesterol in lipid bilayers increased the stability of liposomes and resulted in slower release of paclitaxel (Crosasso et al., 2000) . Accordingly, increased IC50 of the PX-liposomes indicates that they were less toxic than paclitaxel (Table 2) , which might be attributed to the fact that paclitaxel was retained within the phospholipid bilayers or attached to the surface of liposomes. This suggests that ethanol-based proliposome technology has successfully generated liposomes having sustained release properties by demonstrating a depot effect; part of paclitaxel is stored in the lipid bilayer as a depot, so the larger the depot, the longer the action of paclitaxel (Horowitz et al., 1992 , Song et al., 2006 . This also indicates that paclitaxel-loaded liposomes having a size of approximately 100 to 200 nm would remain stable in biological environments; however, further studies should be conducted in vivo to find if a correlation with in vitro findings can be established.
In general, liposomal formulations were also toxic to the SVG-P12 cells, especially for SPC-liposomes, HSPC-liposomes as their IC50 were more than 2000 nM (Table 2 ). This implies that the liposomal formulations would need (Liebmann et al., 1993 , Cahan et al., 1994 . Paclitaxel acts as an inhibitor of cell proliferation in vitro by interfering with the cell cycle development; it works by blocking the cell cycle at G2/M phase and altering the arrangement of spindle microtubules thereby causing cell death (De Brabander et al., 1981 , Jordan et al., 1993 , Straubinger et al., 2004 . Drug-free formulations did not show any toxic effect on glioma as well as normal glial cell lines. Similarly, studies have shown that drug-free liposomes displayed non-toxic effect or effect equal to that of negative control on both cancer and normal cells in vitro (Al-Suwayeh et al., 1996 , Graeser et al., 2009 ). This may be due to that liposomes are prepared from naturally occurring materials such as phospholipids and cholesterol which are major constituents of biological membranes essential for cellular functions.
Phosphatidylcholine forms a major component of the cell membranes and are found in the exoplasmic membrane leaflets. In fact, liposome vesicles might enhance the efficacy of the drugs by binding to the cells and releasing the therapeutic molecules in a sustained manner (Lasic, 1995 , Al-Suwayeh et al., 1996 , Liu et al., 2013 .
Conclusions
In this study, paclitaxel-loaded liposomes were prepared using ethanol-based proliposome technology. The influence of lipid composition (SPC:Chol, HSPC:Chol and DPPC:Chol in equimolar ratio) on the physicochemical properties of formulations, entrapment efficiency of paclitaxel in the liposomes and the cytotoxicity of the formulations were investigated. MLVs generated as a result of hydrating the proliposomes were successfully fragmented into nano-sized liposomes (100-200 nm) using probe-sonication for 10 min. The PI of all the formulations was below 0.3, indicating that sonication time selected was appropriate to form homogenous liposomes.
DPPC-liposomes had more intense surface charge upon using higher paclitaxel concentrations and the pH of DPPC liposomes was found to be the closest to the pH of physiological fluids (pH 7.4) making DPPC liposomes potentially highly appropriate vehicles for the anticancer drug paclitaxel. In addition, entrapment of paclitaxel in DPPC liposomes was generally higher than that in SPC or HSPC vesicles.
The cytotoxicity of paclitaxel-loaded liposomes against U87-MG (grade IV glioma) and SVG-P12 glial cell lines was determined using MTT assay. It was observed that paclitaxel alone was more toxic to U87-MG and SVG-P12 
